| Overview |
| bsm-52556r |
| CD14 Recombinant Antibody |
| WB, IHC-P, IF(ICC), IHC |
| Human |
| Specifications |
| Unconjugated |
| Rabbit |
| Human CD14 between 20-350 amino acids |
| Recombinant |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 929 |
| P08571 |
| Monocyte differentiation antigen CD14, Myeloid cell-specific leucine-rich glycoprotein, CD_antigen: CD14, CD14 |
| Coreceptor for bacterial lipopolysaccharide (PubMed:1698311, PubMed:23264655). In concert with LBP, binds to monomeric lipopolysaccharide and delivers it to the LY96/TLR4 complex, thereby mediating the innate immune response to bacterial lipopolysaccharide (LPS) (PubMed:20133493, PubMed:23264655). Acts via MyD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:8612135). Acts as a coreceptor for TLR2:TLR6 heterodimer in response to diacylated lipopeptides and for TLR2:TLR1 heterodimer in response to triacylated lipopeptides, these clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway (PubMed:16880211). Binds electronegative LDL (LDL-) and mediates the cytokine release induced by LDL- (PubMed:23880187). |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IF(ICC) |
1:50-200 |
| IHC |
|